NEW YORK (GenomeWeb) – Opko Health said this week that it has launched sales of its 4Kscore prostate cancer risk test in additional European territories.

Opko launched the test through its wholly owned subsidiary, Opko Health Spain in partnership with Barnaclínic, a branch of Hospital Clínic de Barcelona. The release follows the US launch of the test earlier this year and a 2012 European launch covering the UK, Ireland, Sweden, and Denmark.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Congress approved a bill Friday that would increase the US National Institutes of Health's funding by $2 billion for fiscal year 2019.

Sarah Lawrence College's Laura Hercher warns in a New York Times op-ed that more people are going to need help figuring out what their consumer genetic testing results mean.

UK's Labour Party calls for a ban on non-invasive prenatal testing for determining sex, BBC News reports.

In PLOS this week: intra-tumor heterogeneity patterns, genomic analysis of Thoroughbred horse origins, and more.

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.